Crizotinib: A Novel Strategy to Reverse Immunosuppression in Melanoma by Targeting Lactate Transport

Abstract

Lactate is a vital metabolite in cancer, significantly impacting tumor progression, metastasis, and overall survival. The CD147–monocarboxylate transporter 1 (MCT1) complex, a major lactate transporter, has emerged as a promising therapeutic target. However, no effective protein–protein interaction (PPI) inhibitors targeting the CD147–MCT1 complex have been identified. In this study, we found that the small-molecule inhibitor crizotinib effectively disrupts the CD147–MCT1 interaction, leading to reduced lactate secretion from melanoma cells and decreased lactate uptake by macrophages. In vivo studies demonstrated that crizotinib treatment significantly suppressed tumor growth and enhanced responsiveness to immune checkpoint blockade therapy. Flow cytometry revealed that this metabolic intervention inhibits M2 polarization and reshapes the tumor immune microenvironment. Transcriptomic analysis further revealed that lactate induces C-X-C motif chemokine ligand 13 (CXCL13) expression in macrophages, which enhances melanoma invasiveness and impairs immune cell-mediated cytotoxicity. Importantly, crizotinib suppresses CXCL13 expression by blocking lactate-driven histone lactylation, thereby reversing the transcriptional reprogramming induced by lactate, as evidenced by reduced histone H3 lysine 18 lactylation (H3K18la) enrichment at the CXCL13 promoter. Taken together, these findings provide new insights into targeting metabolic-immune crosstalk and highlight the value of disrupting CD147–MCT1 interactions to improve immunotherapeutic responses in patients with melanoma.

Keywords

CD147 / CXCL13 / lactate / lactylation / monocarboxylate transporter 1

References

[1] W. H. Koppenol, P. L. Bounds, and C. V. Dang, “Otto Warburg's Contributions to Current Concepts of Cancer Metabolism,” Nature Reviews Cancer 11, no. 5 (2011): 325-337.

[2] J. Guyon, I. Fernandez-Moncada, C. M. Larrieu, et al., “Lactate Dehydrogenases Promote Glioblastoma Growth and Invasion via a Metabolic Symbiosis,” EMBO Molecular Medicine 14, no. 12 (2022): e15343.

[3] S. Oh, S. B. Seo, G. Kim, et al., “Poly-D,L-Lactic Acid Stimulates Angiogenesis and Collagen Synthesis in Aged Animal Skin,” International Journal of Molecular Sciences 24, no. 9 (2023): 7986.

[4] S. Kumagai, S. Koyama, K. Itahashi, et al., “Lactic Acid Promotes PD-1 Expression in Regulatory T Cells in Highly Glycolytic Tumor Microenvironments,” Cancer Cell 40, no. 2 (2022): 201-218.e9.

[5] P. Apostolova and E. L. Pearce, “Lactic Acid and Lactate: Revisiting the Physiological Roles in the Tumor Microenvironment,” Trends in Immunology 43, no. 12 (2022): 969-977.

[6] S. Han, X. Bao, Y. Zou, et al., “d-lactate Modulates M2 Tumor-Associated Macrophages and Remodels Immunosuppressive Tumor Microenvironment for Hepatocellular Carcinoma,” Science Advances 9, no. 29 (2023): eadg2697.

[7] M. Bied, W. W. Ho, F. Ginhoux, and C. Bleriot, “Roles of Macrophages in Tumor Development: A Spatiotemporal Perspective,” Cellular & Molecular Immunology 20, no. 9 (2023): 983-992.

[8] Y. Lin, J. Xu, and H. Lan, “Tumor-Associated Macrophages in Tumor Metastasis: Biological Roles and Clinical Therapeutic Applications,” Journal of Hematology & Oncology 12, no. 1 (2019): 76.

[9] A. Zhang, Y. Xu, H. Xu, et al., “Lactate-Induced M2 Polarization of Tumor-Associated Macrophages Promotes the Invasion of Pituitary Adenoma by Secreting CCL17,” Theranostics 11, no. 8 (2021): 3839-3852.

[10] S. M. P. Vadevoo, G. R. Gunassekaran, C. Lee, et al., “The Macrophage Odorant Receptor Olfr78 Mediates the Lactate-Induced M2 Phenotype of Tumor-Associated Macrophages,” PNAS 118, no. 37 (2021): e2102434118.

[11] D. Zhang, Z. Tang, H. Huang, et al., “Metabolic Regulation of Gene Expression by Histone Lactylation,” Nature 574, no. 7779 (2019): 575-580.

[12] K. Yang, M. Fan, X. Wang, et al., “Lactate Promotes Macrophage HMGB1 Lactylation, Acetylation, and Exosomal Release in Polymicrobial Sepsis,” Cell Death and Differentiation 29, no. 1 (2022): 133-146.

[13] A. De Leo, A. Ugolini, X. Yu, et al., “Glucose-Driven Histone Lactylation Promotes the Immunosuppressive Activity of Monocyte-Derived Macrophages in Glioblastoma,” Immunity 57, no. 5 (2024): 1105-1123.

[14] T. Huang, Q. Feng, Z. Wang, et al., “Tumor-Targeted Inhibition of Monocarboxylate Transporter 1 Improves T-Cell Immunotherapy of Solid Tumors,” Advanced Healthcare Materials 10, no. 4 (2021): e2000549.

[15] J. R. Doherty, C. Yang, K. E. Scott, et al., “Blocking Lactate Export by Inhibiting the Myc Target MCT1 Disables Glycolysis and Glutathione Synthesis,” Cancer Research 74, no. 3 (2014): 908-920.

[16] M. Singh, J. Afonso, D. Sharma, et al., “Targeting Monocarboxylate Transporters (MCTs) in Cancer: How Close Are We to the Clinics?,” Seminars in Cancer Biology 90 (2023): 1-14.

[17] X. Zhang, Y. Guo, T. Xiao, et al., “CD147 Mediates Epidermal Malignant Transformation Through the RSK2/AP-1 Pathway,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022): 246.

[18] Y. Chen, J. Xu, X. Wu, et al., “CD147 Regulates Antitumor CD8+ T-cell Responses to Facilitate Tumor-Immune Escape,” Cellular & Molecular Immunology 18, no. 8 (2021): 1995-2009.

[19] I.-A. Montes-Mojarro, J. Steinhilber, C. M. Griessinger, et al., “CD147 a Direct Target of miR-146a Supports Energy Metabolism and Promotes Tumor Growth in ALK+ ALCL,” Leukemia 36, no. 8 (2022): 2050-2063.

[20] J. Su, X. Chen, and T. Kanekura, “A CD147-Targeting siRNA Inhibits the Proliferation, Invasiveness, and VEGF Production of Human Malignant Melanoma Cells by Down-Regulating Glycolysis,” Cancer Letters 273, no. 1 (2009): 140-147.

[21] P. Kirk, M. C. Wilson, C. Heddle, M. H. Brown, A. N. Barclay, and A. P. Halestrap, “CD147 is Tightly Associated With Lactate Transporters MCT1 and MCT4 and Facilitates Their Cell Surface Expression,” Embo Journal 19, no. 15 (2000): 3896-3904.

[22] A. J. Souers, J. D. Leverson, E. R. Boghaert, et al., “ABT-199, a Potent and Selective BCL-2 Inhibitor, Achieves Antitumor Activity While Sparing Platelets,” Nature Medicine 19, no. 2 (2013): 202-208.

[23] L. Wang, L. Zhang, L. Li, et al., “Small-Molecule Inhibitor Targeting the Hsp90-Cdc37 Protein-Protein Interaction in Colorectal Cancer,” Science Advances 5, no. 9 (2019): eaax2277.

[24] Z.-H. Wang, W.-B. Peng, P. Zhang, X.-P. Yang, and Q. Zhou, “Lactate in the Tumour Microenvironment: From Immune Modulation to Therapy,” EBioMedicine 73 (2021): 103627.

[25] M. Quanz, E. Bender, C. Kopitz, et al., “Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance,” Molecular Cancer Therapeutics 17, no. 11 (2018): 2285-2296.

[26] M. J. Vera, I. Ponce, C. Almarza, et al., “CCL2 and Lactate From Chemotherapeutics-Treated Fibroblasts Drive Malignant Traits by Metabolic Rewiring in Low-Migrating Breast Cancer Cell Lines,” Antioxidants (Basel) 13, no. 7 (2024): 801.

[27] M. Beloueche-Babari, T. Casals Galobart, T. Delgado-Goni, et al., “Monocarboxylate Transporter 1 Blockade With AZD3965 Inhibits Lipid Biosynthesis and Increases Tumour Immune Cell Infiltration,” British Journal of Cancer 122, no. 6 (2020): 895-903.

[28] S. Halford, G. J. Veal, S. R. Wedge, et al., “A Phase I Dose-Escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients With Advanced Cancer,” Clinical Cancer Research 29, no. 8 (2023): 1429-1439.

[29] B. Eichhorst, C. U. Niemann, A. P. Kater, et al., “First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia,” New England Journal of Medicine 388, no. 19 (2023): 1739-1754.

[30] R. Thijssen, L. Tian, M. A. Anderson, et al., “Single-Cell Multiomics Reveal the Scale of Multilayered Adaptations Enabling CLL Relapse During Venetoclax Therapy,” Blood 140, no. 20 (2022): 2127-2141.

[31] C. A. Schiffer, “Promoting Apoptosis With Venetoclax—A Benefit for Older Patients With AML,” New England Journal of Medicine 383, no. 7 (2020): 677-679.

[32] K. Bauer, A. Hauswirth, K. V. Gleixner, et al., “BRD4 Degraders May Effectively Counteract Therapeutic Resistance of Leukemic Stem Cells in AML and ALL,” American Journal of Hematology 99, no. 9 (2024): 1721-1731.

[33] W. Mao, A. Ghasemzadeh, Z. T. Freeman, et al., “Immunogenicity of Prostate Cancer Is Augmented by BET Bromodomain Inhibition,” Journal for ImmunoTherapy of Cancer 7, no. 1 (2019): 277.

[34] J. Wang, Y. Wang, H. Mei, et al., “The BET Bromodomain Inhibitor JQ1 Radiosensitizes Non-Small Cell Lung Cancer Cells by Upregulating p21,” Cancer Letters 391 (2017): 141-151.

[35] V. Maggisano, M. Celano, R. Malivindi, et al., “Nanoparticles Loaded With the BET Inhibitor JQ1 Block the Growth of Triple Negative Breast Cancer Cells in Vitro and in Vivo,” Cancers (Basel) 12, no. 1 (2019): 91.

[36] G. Wei, H. Sun, K. Dong, et al., “The Thermogenic Activity of Adjacent Adipocytes Fuels the Progression of ccRCC and Compromises Anti-Tumor Therapeutic Efficacy,” Cell metabolism 33, no. 10 (2021): 2021-2039.

[37] X. Min, X. Zhang, Y. Li, et al., “HSPA12A Unstabilizes CD147 to Inhibit Lactate Export and Migration in Human Renal Cell Carcinoma,” Theranostics 10, no. 19 (2020): 8573-8590.

[38] Z. Yang, W. Su, X. Wei, et al., “HIF-1α Drives Resistance to Ferroptosis in Solid Tumors by Promoting Lactate Production and Activating SLC1A1,” Cell Reports 42, no. 8 (2023): 112945.

[39] A. T. Shaw, T. M. Bauer, F. de Marinis, et al., “First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer,” New England Journal of Medicine 383, no. 21 (2020): 2018-2029.

[40] M. Certo, C. H. Tsai, V. Pucino, P. C. Ho, and C. Mauro, “Lactate Modulation of Immune Responses in Inflammatory Versus Tumour Microenvironments,” Nature Reviews Immunology 21, no. 3 (2021): 151-161.

[41] J. Zhou, Y. Hu, Y. Cao, et al., “A Lactate-Depleting Metal Organic Framework-Based Nanocatalyst Reinforces Intratumoral T Cell Response to Boost Anti-PD1 Immunotherapy,” Journal of Colloid & Interface Science 660 (2024): 869-884.

[42] N. Li, Y. Kang, L. Wang, et al., “ALKBH5 Regulates anti-PD-1 Therapy Response by Modulating Lactate and Suppressive Immune Cell Accumulation in Tumor Microenvironment,” PNAS 117, no. 33 (2020): 20159-20170.

[43] A. Christofides, L. Strauss, A. Yeo, C. Cao, A. Charest, and V. A. Boussiotis, “The Complex Role of Tumor-Infiltrating Macrophages,” Nature Immunology 23, no. 8 (2022): 1148-1156.

[44] K. Yang, J. Xu, M. Fan, et al., “Lactate Suppresses Macrophage Pro-Inflammatory Response to LPS Stimulation by Inhibition of YAP and NF-kappaB Activation via GPR81-Mediated Signaling,” Frontiers in Immunology 11 (2020): 587913.

[45] N. Wang, W. Wang, and X. Wang, “Histone Lactylation Boosts Reparative Gene Activation Post-Myocardial Infarction,” Circulation Research 131, no. 11 (2022): 893-908.

[46] Y. Liu, S. Liang, D. Jiang, et al., “Manipulation of TAMs Functions to Facilitate the Immune Therapy Effects of Immune Checkpoint Antibodies,” Journal of Controlled Release 336 (2021): 621-634.

[47] M. Larroquette, J. P. Guegan, B. Besse, et al., “Spatial Transcriptomics of Macrophage Infiltration in Non-Small Cell Lung Cancer Reveals Determinants of Sensitivity and Resistance to Anti-PD1/PD-L1 Antibodies,” Journal for ImmunoTherapy of Cancer 10, no. 5 (2022): e003890.

[48] S. Zhao, Y. Mi, B. Guan, et al., “Tumor-Derived Exosomal miR-934 Induces Macrophage M2 Polarization to Promote Liver Metastasis of Colorectal Cancer,” Journal of Hematology & Oncology 13, no. 1 (2020): 156.

[49] X. Chen, Y. Takemoto, H. Deng, et al., “Histidine Decarboxylase (HDC)-Expressing Granulocytic Myeloid Cells Induce and Recruit Foxp3(+) Regulatory T Cells in Murine Colon Cancer,” Oncoimmunology 6, no. 3 (2017): e1290034.

[50] G. Multhoff and P. Vaupel, “Lactate-Avid Regulatory T Cells: Metabolic Plasticity Controls Immunosuppression in Tumour Microenvironment,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 171.

[51] D. Raychaudhuri, P. Singh, B. Chakraborty, et al., “Histone Lactylation Drives CD8(+) T Cell Metabolism and Function,” Nature Immunology 25, no. 11 (2024): 2140-2151.

[52] K. Sun, X. Zhang, J. Shi, et al., “Elevated Protein Lactylation Promotes Immunosuppressive Microenvironment and Therapeutic Resistance in Pancreatic Ductal Adenocarcinoma,” Journal of Clinical Investigation 135, no. 7 (2025): e187024.

[53] J. Yu, P. Chai, M. Xie, et al., “Histone Lactylation Drives Oncogenesis by Facilitating m6A Reader Protein YTHDF2 Expression in Ocular Melanoma,” Genome Biology 22, no. 1 (2021): 85.

[54] X.-M. Li, Y. Yang, F.-Q. Jiang, et al., “Histone Lactylation Inhibits RARγ Expression in Macrophages to Promote Colorectal Tumorigenesis Through Activation of TRAF6-IL-6-STAT3 Signaling,” Cell Reports 43, no. 2 (2024): 113688.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.